Loading…

GATA3 Expression in Prostatic Adenosquamous Carcinoma: A Potential Diagnostic Pitfall

Urothelial carcinoma and prostatic adenocarcinoma can have overlapping histologic features and in some instances pose challenges to pathologists. GATA binding protein 3 (GATA3) immunohistochemistry (IHC) is a well-established tool to aid in this specific diagnostic dilemma as it has been shown to be...

Full description

Saved in:
Bibliographic Details
Published in:International journal of surgical pathology 2024-04, p.10668969241241640-10668969241241640
Main Authors: Potterveld, Susan K, Williamson, Sean R, Al-Obaidy, Khaleel I, Akgul, Mahmut, Chan, Emily, Giannico, Giovanna A, Sangoi, Ankur R
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c253t-f36cf126df20e8811d5ef3d453504a8b80d5c600ab09c2e0b1df88ce6e13a4b63
container_end_page 10668969241241640
container_issue
container_start_page 10668969241241640
container_title International journal of surgical pathology
container_volume
creator Potterveld, Susan K
Williamson, Sean R
Al-Obaidy, Khaleel I
Akgul, Mahmut
Chan, Emily
Giannico, Giovanna A
Sangoi, Ankur R
description Urothelial carcinoma and prostatic adenocarcinoma can have overlapping histologic features and in some instances pose challenges to pathologists. GATA binding protein 3 (GATA3) immunohistochemistry (IHC) is a well-established tool to aid in this specific diagnostic dilemma as it has been shown to be a sensitive marker for urothelial carcinoma and a putatively specific marker in excluding prostatic adenocarcinoma. However, in encountering an index tumor of prostatic adenosquamous carcinoma positive for GATA3, herein we sought to investigate this potential diagnostic pitfall in a larger series of tumors. In this study, we retrospectively reviewed prostatic adenosquamous carcinomas diagnosed in 17 patients across the authors' institutions and personal consult collections in the past 10 years. GATA3 IHC was either reviewed or performed on tumors not previously tested. We also recorded other immunostains that were performed at initial diagnosis. Positivity for GATA3 was found in 9 of 17 (53%) tumors, all within squamous regions (2 tumors also showed concomitant moderate GATA3 positivity within glandular elements). The GATA3 positive tumors were all positive for p63 in the 7 tumors where p63 was also performed. Of all tumors tested, NKX3.1 was positive in 100% (13/13) of the glandular elements (3 tumors also showed NKX3.1 concomitant positivity within squamous regions). In summary, when encountering a carcinoma with mixed glandular/squamous features in which prostatic origin is being considered, awareness of GATA3 immunoreactivity in a subset of prostatic adenosquamous carcinoma is critical to avoid diagnostic pitfalls.
doi_str_mv 10.1177/10668969241241640
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3031131000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3031131000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c253t-f36cf126df20e8811d5ef3d453504a8b80d5c600ab09c2e0b1df88ce6e13a4b63</originalsourceid><addsrcrecordid>eNplkE9LAzEQxYMotlY_gBfJ0cvqTJJNs96WWqtQcA_teclmsxLZP-1mF_Tbm9LqRRiYgfm9x8wj5BbhAXE-f0SQUiUyYQJDSQFnZIqJgIgJGZ-HOeyjAzAhV95_AgCTDC_JhKtYMhDzKdmu0k3K6fJr11vvXddS19Ks7_ygB2doWtq28_tRN93o6UL3xrVdo59oSrNusO3gdE2fnf4I1IHP3FDpur4mF6F5e3PqM7J9WW4Wr9H6ffW2SNeRYTEfoopLUyGTZcXAKoVYxrbipYh5DEKrQkEZGwmgC0gMs1BgWSllrLTItSgkn5H7o--u7_aj9UPeOG9sXevWhoNzDhyRY3g8oHhETXjO97bKd71rdP-dI-SHNPN_aQbN3cl-LBpb_il-4-M_zu1uxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3031131000</pqid></control><display><type>article</type><title>GATA3 Expression in Prostatic Adenosquamous Carcinoma: A Potential Diagnostic Pitfall</title><source>SAGE</source><creator>Potterveld, Susan K ; Williamson, Sean R ; Al-Obaidy, Khaleel I ; Akgul, Mahmut ; Chan, Emily ; Giannico, Giovanna A ; Sangoi, Ankur R</creator><creatorcontrib>Potterveld, Susan K ; Williamson, Sean R ; Al-Obaidy, Khaleel I ; Akgul, Mahmut ; Chan, Emily ; Giannico, Giovanna A ; Sangoi, Ankur R</creatorcontrib><description>Urothelial carcinoma and prostatic adenocarcinoma can have overlapping histologic features and in some instances pose challenges to pathologists. GATA binding protein 3 (GATA3) immunohistochemistry (IHC) is a well-established tool to aid in this specific diagnostic dilemma as it has been shown to be a sensitive marker for urothelial carcinoma and a putatively specific marker in excluding prostatic adenocarcinoma. However, in encountering an index tumor of prostatic adenosquamous carcinoma positive for GATA3, herein we sought to investigate this potential diagnostic pitfall in a larger series of tumors. In this study, we retrospectively reviewed prostatic adenosquamous carcinomas diagnosed in 17 patients across the authors' institutions and personal consult collections in the past 10 years. GATA3 IHC was either reviewed or performed on tumors not previously tested. We also recorded other immunostains that were performed at initial diagnosis. Positivity for GATA3 was found in 9 of 17 (53%) tumors, all within squamous regions (2 tumors also showed concomitant moderate GATA3 positivity within glandular elements). The GATA3 positive tumors were all positive for p63 in the 7 tumors where p63 was also performed. Of all tumors tested, NKX3.1 was positive in 100% (13/13) of the glandular elements (3 tumors also showed NKX3.1 concomitant positivity within squamous regions). In summary, when encountering a carcinoma with mixed glandular/squamous features in which prostatic origin is being considered, awareness of GATA3 immunoreactivity in a subset of prostatic adenosquamous carcinoma is critical to avoid diagnostic pitfalls.</description><identifier>ISSN: 1066-8969</identifier><identifier>EISSN: 1940-2465</identifier><identifier>DOI: 10.1177/10668969241241640</identifier><identifier>PMID: 38562047</identifier><language>eng</language><publisher>United States</publisher><ispartof>International journal of surgical pathology, 2024-04, p.10668969241241640-10668969241241640</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c253t-f36cf126df20e8811d5ef3d453504a8b80d5c600ab09c2e0b1df88ce6e13a4b63</cites><orcidid>0000-0002-3898-1460 ; 0000-0003-0874-8964 ; 0000-0001-9890-8751 ; 0000-0002-7290-4004 ; 0000-0001-7948-2337 ; 0000-0003-0929-0940 ; 0000-0002-0326-3207</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38562047$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Potterveld, Susan K</creatorcontrib><creatorcontrib>Williamson, Sean R</creatorcontrib><creatorcontrib>Al-Obaidy, Khaleel I</creatorcontrib><creatorcontrib>Akgul, Mahmut</creatorcontrib><creatorcontrib>Chan, Emily</creatorcontrib><creatorcontrib>Giannico, Giovanna A</creatorcontrib><creatorcontrib>Sangoi, Ankur R</creatorcontrib><title>GATA3 Expression in Prostatic Adenosquamous Carcinoma: A Potential Diagnostic Pitfall</title><title>International journal of surgical pathology</title><addtitle>Int J Surg Pathol</addtitle><description>Urothelial carcinoma and prostatic adenocarcinoma can have overlapping histologic features and in some instances pose challenges to pathologists. GATA binding protein 3 (GATA3) immunohistochemistry (IHC) is a well-established tool to aid in this specific diagnostic dilemma as it has been shown to be a sensitive marker for urothelial carcinoma and a putatively specific marker in excluding prostatic adenocarcinoma. However, in encountering an index tumor of prostatic adenosquamous carcinoma positive for GATA3, herein we sought to investigate this potential diagnostic pitfall in a larger series of tumors. In this study, we retrospectively reviewed prostatic adenosquamous carcinomas diagnosed in 17 patients across the authors' institutions and personal consult collections in the past 10 years. GATA3 IHC was either reviewed or performed on tumors not previously tested. We also recorded other immunostains that were performed at initial diagnosis. Positivity for GATA3 was found in 9 of 17 (53%) tumors, all within squamous regions (2 tumors also showed concomitant moderate GATA3 positivity within glandular elements). The GATA3 positive tumors were all positive for p63 in the 7 tumors where p63 was also performed. Of all tumors tested, NKX3.1 was positive in 100% (13/13) of the glandular elements (3 tumors also showed NKX3.1 concomitant positivity within squamous regions). In summary, when encountering a carcinoma with mixed glandular/squamous features in which prostatic origin is being considered, awareness of GATA3 immunoreactivity in a subset of prostatic adenosquamous carcinoma is critical to avoid diagnostic pitfalls.</description><issn>1066-8969</issn><issn>1940-2465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNplkE9LAzEQxYMotlY_gBfJ0cvqTJJNs96WWqtQcA_teclmsxLZP-1mF_Tbm9LqRRiYgfm9x8wj5BbhAXE-f0SQUiUyYQJDSQFnZIqJgIgJGZ-HOeyjAzAhV95_AgCTDC_JhKtYMhDzKdmu0k3K6fJr11vvXddS19Ks7_ygB2doWtq28_tRN93o6UL3xrVdo59oSrNusO3gdE2fnf4I1IHP3FDpur4mF6F5e3PqM7J9WW4Wr9H6ffW2SNeRYTEfoopLUyGTZcXAKoVYxrbipYh5DEKrQkEZGwmgC0gMs1BgWSllrLTItSgkn5H7o--u7_aj9UPeOG9sXevWhoNzDhyRY3g8oHhETXjO97bKd71rdP-dI-SHNPN_aQbN3cl-LBpb_il-4-M_zu1uxQ</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Potterveld, Susan K</creator><creator>Williamson, Sean R</creator><creator>Al-Obaidy, Khaleel I</creator><creator>Akgul, Mahmut</creator><creator>Chan, Emily</creator><creator>Giannico, Giovanna A</creator><creator>Sangoi, Ankur R</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3898-1460</orcidid><orcidid>https://orcid.org/0000-0003-0874-8964</orcidid><orcidid>https://orcid.org/0000-0001-9890-8751</orcidid><orcidid>https://orcid.org/0000-0002-7290-4004</orcidid><orcidid>https://orcid.org/0000-0001-7948-2337</orcidid><orcidid>https://orcid.org/0000-0003-0929-0940</orcidid><orcidid>https://orcid.org/0000-0002-0326-3207</orcidid></search><sort><creationdate>20240401</creationdate><title>GATA3 Expression in Prostatic Adenosquamous Carcinoma: A Potential Diagnostic Pitfall</title><author>Potterveld, Susan K ; Williamson, Sean R ; Al-Obaidy, Khaleel I ; Akgul, Mahmut ; Chan, Emily ; Giannico, Giovanna A ; Sangoi, Ankur R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c253t-f36cf126df20e8811d5ef3d453504a8b80d5c600ab09c2e0b1df88ce6e13a4b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Potterveld, Susan K</creatorcontrib><creatorcontrib>Williamson, Sean R</creatorcontrib><creatorcontrib>Al-Obaidy, Khaleel I</creatorcontrib><creatorcontrib>Akgul, Mahmut</creatorcontrib><creatorcontrib>Chan, Emily</creatorcontrib><creatorcontrib>Giannico, Giovanna A</creatorcontrib><creatorcontrib>Sangoi, Ankur R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of surgical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Potterveld, Susan K</au><au>Williamson, Sean R</au><au>Al-Obaidy, Khaleel I</au><au>Akgul, Mahmut</au><au>Chan, Emily</au><au>Giannico, Giovanna A</au><au>Sangoi, Ankur R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GATA3 Expression in Prostatic Adenosquamous Carcinoma: A Potential Diagnostic Pitfall</atitle><jtitle>International journal of surgical pathology</jtitle><addtitle>Int J Surg Pathol</addtitle><date>2024-04-01</date><risdate>2024</risdate><spage>10668969241241640</spage><epage>10668969241241640</epage><pages>10668969241241640-10668969241241640</pages><issn>1066-8969</issn><eissn>1940-2465</eissn><abstract>Urothelial carcinoma and prostatic adenocarcinoma can have overlapping histologic features and in some instances pose challenges to pathologists. GATA binding protein 3 (GATA3) immunohistochemistry (IHC) is a well-established tool to aid in this specific diagnostic dilemma as it has been shown to be a sensitive marker for urothelial carcinoma and a putatively specific marker in excluding prostatic adenocarcinoma. However, in encountering an index tumor of prostatic adenosquamous carcinoma positive for GATA3, herein we sought to investigate this potential diagnostic pitfall in a larger series of tumors. In this study, we retrospectively reviewed prostatic adenosquamous carcinomas diagnosed in 17 patients across the authors' institutions and personal consult collections in the past 10 years. GATA3 IHC was either reviewed or performed on tumors not previously tested. We also recorded other immunostains that were performed at initial diagnosis. Positivity for GATA3 was found in 9 of 17 (53%) tumors, all within squamous regions (2 tumors also showed concomitant moderate GATA3 positivity within glandular elements). The GATA3 positive tumors were all positive for p63 in the 7 tumors where p63 was also performed. Of all tumors tested, NKX3.1 was positive in 100% (13/13) of the glandular elements (3 tumors also showed NKX3.1 concomitant positivity within squamous regions). In summary, when encountering a carcinoma with mixed glandular/squamous features in which prostatic origin is being considered, awareness of GATA3 immunoreactivity in a subset of prostatic adenosquamous carcinoma is critical to avoid diagnostic pitfalls.</abstract><cop>United States</cop><pmid>38562047</pmid><doi>10.1177/10668969241241640</doi><orcidid>https://orcid.org/0000-0002-3898-1460</orcidid><orcidid>https://orcid.org/0000-0003-0874-8964</orcidid><orcidid>https://orcid.org/0000-0001-9890-8751</orcidid><orcidid>https://orcid.org/0000-0002-7290-4004</orcidid><orcidid>https://orcid.org/0000-0001-7948-2337</orcidid><orcidid>https://orcid.org/0000-0003-0929-0940</orcidid><orcidid>https://orcid.org/0000-0002-0326-3207</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1066-8969
ispartof International journal of surgical pathology, 2024-04, p.10668969241241640-10668969241241640
issn 1066-8969
1940-2465
language eng
recordid cdi_proquest_miscellaneous_3031131000
source SAGE
title GATA3 Expression in Prostatic Adenosquamous Carcinoma: A Potential Diagnostic Pitfall
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T12%3A23%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GATA3%20Expression%20in%20Prostatic%20Adenosquamous%20Carcinoma:%20A%20Potential%20Diagnostic%20Pitfall&rft.jtitle=International%20journal%20of%20surgical%20pathology&rft.au=Potterveld,%20Susan%20K&rft.date=2024-04-01&rft.spage=10668969241241640&rft.epage=10668969241241640&rft.pages=10668969241241640-10668969241241640&rft.issn=1066-8969&rft.eissn=1940-2465&rft_id=info:doi/10.1177/10668969241241640&rft_dat=%3Cproquest_cross%3E3031131000%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c253t-f36cf126df20e8811d5ef3d453504a8b80d5c600ab09c2e0b1df88ce6e13a4b63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3031131000&rft_id=info:pmid/38562047&rfr_iscdi=true